Digoxin antibodies Fab fragments clinical trials
How each study uses digoxin antibodies Fab fragments is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 22 Apr 1986 · Digibind · BLA 103141 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
University of Maryland, Baltimore (1) · Rambam Health Care Campus (1) · AMAG Pharmaceuticals, Inc. (1) · National Institute on Aging (NIA) (1)
Studies
Open first, then newest update. How each study uses digoxin antibodies Fab fragments is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKICompletedPhase 4University of Maryland, BaltimoreNCT03810417Written as Digoxin Antibodies Fab FragmentsHow we know
- Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaTerminatedPhase 2/3AMAG Pharmaceuticals, Inc.NCT03008616Written as AMAG-423 (digoxin immune fab)How we know
- Antibodies to Digoxin for Bipolar DisorderCompletedPhase 2Rambam Health Care CampusNCT00550576Written as Digibind (Fab)How we know
- Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal DiseaseStatus unknownPhase 4National Institute on Aging (NIA)NCT00852787Written as Digoxin immune fabHow we know
Codes
What other systems call digoxin antibodies Fab fragments · ClinicalTrials.gg INT003293
- MeSH (NLM) C050199digoxin antibodies Fab fragmentsOne source ClinicalTrials.gov
- RxNorm 1745257One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C050199 | digoxin antibodies Fab fragments | One source ClinicalTrials.gov |
| RxNorm | 1745257 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.